somes

Clinical Trials and Supply of GMO-based Medicines for COVID-19

Summary

This regulation facilitates clinical trials and the supply of medicinal products containing genetically modified organisms to combat COVID-19.
9 17.07.2020
Other
health
pharmacy
environment
european union

Key points

  • Facilitation of clinical trials involving genetically modified organisms specifically for COVID-19 treatments.
  • Streamlining the supply and distribution of medicines containing GMOs to combat the pandemic.
  • Creation of a specialized legal framework to accelerate medical responses during health emergencies.
Documents (PDFs)
Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease ***I
These raw data are provided by the Open Data Portal of the European Union (data.europa.eu) and are licensed under ODC-BY 1.0.